PriceTargets.com logo

Envista - NVST Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.65
  • Forecasted Upside: 10.45%
  • Number of Analysts: 16
  • Breakdown:
  • 2 Sell Ratings
  • 11 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.70 As of 12/20/2024 06:31 PM ET
▲ +0.67 (3.72%)

This chart shows the closing price for NVST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Envista Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVST

Analyst Price Target is $20.65
▲ +10.45% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Envista in the last 3 months. The average price target is $20.65, with a high forecast of $26.00 and a low forecast of $16.00. The average price target represents a 10.45% upside from the last price of $18.70.

This chart shows the closing price for NVST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in Envista. This rating has held steady since June 2024, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 3 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 3 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 1 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 2 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 11 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/4/2024MizuhoInitiated CoverageUnderperform$20.00
10/31/2024Leerink PartnrsUpgradeStrong Sell ➝ Hold
10/31/2024Piper SandlerBoost TargetNeutral ➝ Neutral$16.00 ➝ $17.00
10/31/2024Needham & Company LLCReiterated RatingHold
10/31/2024Robert W. BairdBoost TargetNeutral ➝ Neutral$17.00 ➝ $22.00
10/31/2024Leerink PartnersUpgradeUnderperform ➝ Market Perform$16.00 ➝ $23.00
10/23/2024Stifel NicolausBoost TargetBuy ➝ Buy$18.00 ➝ $21.00
10/8/2024Wells Fargo & CompanyInitiated CoverageEqual Weight$20.00
9/23/2024Evercore ISIBoost TargetOutperform ➝ Outperform$18.00 ➝ $23.00
8/8/2024Bank of AmericaLower TargetBuy ➝ Buy$22.00 ➝ $19.00
8/8/2024Evercore ISILower TargetOutperform ➝ Outperform$19.00 ➝ $18.00
8/8/2024Needham & Company LLCReiterated RatingHold
8/8/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$23.00 ➝ $16.00
7/30/2024Stifel NicolausLower TargetBuy ➝ Buy$20.00 ➝ $18.00
7/30/2024Piper SandlerLower TargetNeutral ➝ Neutral$18.00 ➝ $16.00
7/22/2024Robert W. BairdLower TargetNeutral ➝ Neutral$19.00 ➝ $17.00
7/16/2024Needham & Company LLCReiterated RatingHold
6/25/2024Evercore ISILower TargetOutperform ➝ Outperform$24.00 ➝ $19.00
6/3/2024Needham & Company LLCReiterated RatingHold
5/3/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$20.00 ➝ $17.50
5/2/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$29.00 ➝ $23.00
5/2/2024Needham & Company LLCReiterated RatingHold
5/2/2024Robert W. BairdLower TargetNeutral ➝ Neutral$22.00 ➝ $19.00
4/26/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$33.00 ➝ $21.00
2/26/2024Leerink PartnrsReiterated RatingUnderperform
2/26/2024Leerink PartnersInitiated CoverageUnderperform$19.00
2/9/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00 ➝ $23.00
2/8/2024William BlairDowngradeOutperform ➝ Market Perform
1/5/2024UBS GroupInitiated CoverageNeutral$26.00
12/11/2023The Goldman Sachs GroupDowngradeBuy ➝ Sell$22.00
11/16/2023Needham & Company LLCInitiated CoverageHold
11/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$41.00 ➝ $28.00
11/2/2023Morgan StanleyLower TargetOverweight ➝ Overweight$42.00 ➝ $38.00
11/2/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$42.00 ➝ $32.00
11/2/2023Piper SandlerDowngradeOverweight ➝ Neutral$39.00 ➝ $25.00
11/1/2023Stifel NicolausLower TargetBuy ➝ Buy$45.00 ➝ $36.00
10/26/2023Piper SandlerLower TargetOverweight ➝ Overweight$46.00 ➝ $39.00
10/20/2023Morgan StanleyLower TargetOverweight ➝ Overweight$46.00 ➝ $42.00
10/11/2023Evercore ISILower Target$40.00 ➝ $30.00
7/11/2023Bank of AmericaLower Target$47.00 ➝ $45.00
2/9/2023Robert W. BairdBoost TargetNeutral$38.00 ➝ $43.00
2/6/2023Piper SandlerBoost TargetOverweight$42.00 ➝ $46.00
11/4/2022Piper SandlerLower TargetOverweight$46.00 ➝ $44.00
11/3/2022William BlairReiterated RatingOutperform
10/13/2022Morgan StanleyLower TargetOverweight$49.00 ➝ $48.00
8/29/2022Piper SandlerUpgradeNeutral ➝ Overweight$40.00 ➝ $46.00
8/9/2022Evercore ISILower Target$44.00
8/4/2022Morgan StanleyLower TargetOverweight$53.00 ➝ $49.00
8/4/2022Piper SandlerLower TargetNeutral$43.00 ➝ $40.00
7/21/2022The Goldman Sachs GroupLower TargetBuy$58.00 ➝ $45.00
7/20/2022Morgan StanleyLower TargetOverweight$56.00 ➝ $53.00
7/11/2022Piper SandlerLower Target$49.00 ➝ $43.00
6/17/2022Stifel NicolausLower Target$55.00 ➝ $50.00
6/14/2022Robert W. BairdDowngradeOutperform ➝ Neutral$54.00 ➝ $46.00
5/5/2022Piper SandlerLower Target$50.00 ➝ $49.00
4/5/2022Robert W. BairdReiterated RatingOutperform ➝ Outperform$54.00
4/4/2022Morgan StanleyBoost TargetOverweight$52.00 ➝ $56.00
2/10/2022Morgan StanleyBoost TargetOverweight$48.00 ➝ $52.00
2/10/2022Piper SandlerBoost Target$47.00 ➝ $50.00
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$48.00
1/7/2022Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $45.00
10/26/2021Bank of AmericaUpgradeNeutral ➝ Buy$49.00 ➝ $48.00
8/4/2021Piper SandlerBoost TargetNeutral$45.00 ➝ $47.00
5/7/2021Morgan StanleyBoost TargetEqual Weight$42.00 ➝ $46.00
5/6/2021Credit Suisse GroupBoost TargetOutperform$49.00 ➝ $55.00
5/6/2021Piper SandlerBoost TargetNeutral$41.00 ➝ $45.00
3/25/2021Credit Suisse GroupBoost TargetOutperform$44.00 ➝ $46.00
2/12/2021Morgan StanleyBoost TargetEqual Weight$36.00 ➝ $42.00
2/11/2021Credit Suisse GroupBoost TargetOutperform$41.00 ➝ $44.00
2/11/2021Piper SandlerBoost TargetNeutral$28.00 ➝ $41.00
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$31.00 ➝ $41.00
12/15/2020Morgan StanleyBoost TargetEqual Weight$28.00 ➝ $36.00
11/25/2020Bank of AmericaBoost TargetNeutral$30.00 ➝ $32.00
11/2/2020Morgan StanleyBoost TargetEqual Weight$24.00 ➝ $28.00
10/30/2020William BlairReiterated RatingOutperform
10/30/2020Piper SandlerBoost Target$22.00 ➝ $28.00
10/30/2020JPMorgan Chase & Co.Boost TargetOverweight$28.00 ➝ $30.00
10/30/2020Credit Suisse GroupBoost TargetNeutral$25.00 ➝ $31.00
10/30/2020JPMorgan Chase & Co.Reiterated RatingOverweight$28.00 ➝ $30.00
9/15/2020Bank of AmericaBoost TargetNeutral$23.00 ➝ $27.00
8/3/2020Morgan StanleyBoost TargetEqual Weight$18.00 ➝ $24.00
7/31/2020Piper SandlerBoost TargetNeutral$20.00 ➝ $22.00
7/20/2020Bank of AmericaBoost TargetNeutral$21.50 ➝ $23.00
6/16/2020Piper SandlerInitiated CoverageNeutral$20.00
6/1/2020JPMorgan Chase & Co.Boost TargetOverweight$22.00 ➝ $24.00
5/14/2020Morgan StanleyLower TargetEqual Weight$20.00 ➝ $18.00
5/13/2020Robert W. BairdLower TargetOutperform$25.00 ➝ $23.00
5/13/2020Bank of AmericaReiterated RatingNeutral$19.50 ➝ $18.00
5/13/2020Credit Suisse GroupLower TargetNeutral$23.00 ➝ $21.00
3/17/2020JPMorgan Chase & Co.Lower TargetOverweight$32.00 ➝ $27.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.36 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 15 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 15 very positive mentions
  • 18 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 12 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 20 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 13 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 25 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 25 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Envista logo
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Read More

Today's Range

Now: $18.70
Low: $17.92
High: $18.77

50 Day Range

MA: $20.14
Low: $17.70
High: $22.33

52 Week Range

Now: $18.70
Low: $15.15
High: $25.64

Volume

6,189,164 shs

Average Volume

2,383,075 shs

Market Capitalization

$3.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Envista?

The following Wall Street sell-side analysts have issued reports on Envista in the last year: Bank of America Co., Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Robert W. Baird, Stifel Nicolaus, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for NVST.

What is the current price target for Envista?

0 Wall Street analysts have set twelve-month price targets for Envista in the last year. Their average twelve-month price target is $20.65, suggesting a possible upside of 10.4%. UBS Group AG has the highest price target set, predicting NVST will reach $26.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $16.00 for Envista in the next year.
View the latest price targets for NVST.

What is the current consensus analyst rating for Envista?

Envista currently has 2 sell ratings, 11 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NVST, but not buy more shares or sell existing shares.
View the latest ratings for NVST.

What other companies compete with Envista?

Other companies that are similar to Envista include Solventum, Smith & Nephew, Penumbra, Glaukos and Bausch + Lomb. Learn More about companies similar to Envista.

How do I contact Envista's investor relations team?

Envista's physical mailing address is 200 S. KRAEMER BLVD. BUILDING E, BREA CA, 92821. The company's listed phone number is 714-817-7000 and its investor relations email address is [email protected]. The official website for Envista is www.envistaco.com. Learn More about contacing Envista investor relations.